The disclosure comes as another of Arcus's TIGIT trials flops.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.
The EU recommendation for odronextamab comes after a US rejection in March.
But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.
The group plays down upcoming interim analysis, but still hopes for accelerated approval.
Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.